6,198 AstraZeneca Plc $AZN Shares Sold by Keybank National Association OH

Keybank National Association OH decreased its position in AstraZeneca Plc (NYSE:AZN) by 14.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,946 shares of the company’s stock after selling 6,198 shares during the period. Keybank National Association OH’s holdings in AstraZeneca were worth $6,127,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Amundi raised its holdings in AstraZeneca by 146,574.4% during the first quarter. Amundi now owns 15,386,149 shares of the company’s stock worth $3,034,456,000 after purchasing an additional 15,375,659 shares in the last quarter. Janus Henderson Group PLC lifted its position in AstraZeneca by 889.9% in the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock valued at $2,319,947,000 after purchasing an additional 10,742,268 shares during the period. Rathbones Group PLC lifted its position in AstraZeneca by 106,772.0% in the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after purchasing an additional 8,047,406 shares during the period. Royal Bank of Canada boosted its holdings in AstraZeneca by 208.6% in the 1st quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock valued at $2,048,417,000 after purchasing an additional 7,021,126 shares in the last quarter. Finally, Swiss National Bank purchased a new stake in AstraZeneca in the 1st quarter valued at approximately $1,202,714,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZN opened at $184.46 on Friday. The company has a 50-day simple moving average of $168.42 and a 200-day simple moving average of $180.21. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $286.08 billion, a PE ratio of 26.09, a P/E/G ratio of 1.44 and a beta of 0.24. AstraZeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Friday, October 30th. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.60 by $0.19. The firm had revenue of $16.21 billion during the quarter, compared to analysts’ expectations of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The business’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.38 earnings per share. Equities research analysts predict that AstraZeneca Plc will post 10.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AZN. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Deutsche Bank raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Finally, Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $206.67.

AstraZeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.